NEW YORK, March 3 (Reuters) - A long-awaited experimental diabetes medicine from Eli Lilly & Co and Amylin Pharmaceuticals Inc , that patients need to inject only once a week, failed to match a rival ...
WASHINGTON (AP) - Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections ...
) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON™ (exenatide extended-release for injectable suspension) – the first once-weekly treatment for type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results